Does Cosentyx Affect Vaccine Potency?
Cosentyx (secukinumab), an IL-17 inhibitor for psoriasis and other conditions, can reduce immune responses to some vaccines. Clinical data show it lowers antibody titers against non-live vaccines like tetanus toxoid and pneumococcal polysaccharide vaccine (PPSV-23). In trials, fewer patients on Cosentyx achieved protective levels compared to placebo [1][2].
Which Vaccines Are Impacted?
- Non-live vaccines: Reduced efficacy for influenza, tetanus, pneumococcal (PPSV-23), and hepatitis B. Live vaccines like MMR or varicella are contraindicated due to immunosuppression risk [1][2].
- COVID-19 vaccines: Real-world studies indicate lower seroconversion rates (e.g., 60-80% vs. 90%+ in controls for mRNA vaccines), though protection against severe disease remains [3].
No major impact on all vaccines; protein-based or mRNA types show variable but often diminished responses.
How Does Cosentyx Interfere?
It blocks IL-17, disrupting T-cell help for B-cell antibody production. This primarily affects humoral immunity without fully ablating cellular responses. Effects peak during active treatment but wane after discontinuation (e.g., titers recover 6-12 months post-stop) [1][4].
Recommendations for Patients on Cosentyx
Prescribing info advises avoiding live vaccines. For non-live, vaccinate before starting Cosentyx if possible, or monitor titers/boosters during therapy. Timing: Administer vaccines during drug "washout" periods if feasible [1][2]. Consult immunologist for high-risk patients.
Real-World Evidence and Risks
Post-marketing studies confirm ~20-30% lower vaccine response rates. No increased breakthrough infections reported solely from reduced potency, but infection risk rises with underlying disease [3][4]. Pediatric data limited; similar patterns in adults.
Alternatives or Management Strategies
Switch to IL-23 inhibitors (e.g., Tremfya) or JAK inhibitors, which show less vaccine interference in head-to-head trials [5]. Pre-treatment serology testing helps identify non-responders.
Sources
[1] [Cosentyx Prescribing Information]
[2] [Bagci et al., J Dtsch Dermatol Ges (2019)]
[3] [Winthrop et al., Ann Rheum Dis (2023)]
[4] [DrugPatentWatch: Cosentyx Overview]
[5] [EULAR 2023 Abstracts]